IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, disclosed its second quarter 2026 financial results on July 28, 2026. The Durham, North Carolina-based company released its earnings announcement through a press release posted to its corporate website. The disclosure provides investors with updated operational and financial performance metrics for the period ended June 30, 2026.

Key Points

  • NYSE: IQV
  • IQVIA Holdings Inc. announced its second quarter 2026 financial results on July 28, 2026, for the period ended June 30, 2026
  • The company posted financial performance data through an official press release distributed on its corporate website
  • Investors may review the complete disclosure via the company's investor relations channels and regulatory filings

IQVIA's Quarterly Results Announcement and Disclosure Method

On July 28, 2026, IQVIA Holdings Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. The announcement was posted on the company's internet website and has been furnished to the Securities and Exchange Commission as part of the company's periodic reporting obligations. This disclosure method reflects standard practice for publicly traded companies to communicate quarterly performance data to shareholders, analysts, and market participants through coordinated press releases and regulatory filings.

The press release, filed as Exhibit 99.1 in the company's current report, contains the full text of the quarterly results announcement. IQVIA, headquartered at 2400 Ellis Road in Durham, North Carolina, maintains its disclosure website as a primary channel for distributing investor communications. The company's common stock trades on the New York Stock Exchange under the ticker symbol IQV, with par value of $0.01 per share.

IQVIA's Position in the Healthcare Data and Analytics Sector

IQVIA Holdings Inc. operates as a global provider of advanced analytics, technology solutions, and contract research services serving the life sciences industry. The company's business model encompasses data analytics, technology platforms, and research capabilities that support pharmaceutical companies, healthcare providers, and regulatory bodies. As a publicly traded entity with its common stock listed on the New York Stock Exchange, IQVIA serves a broad range of clients requiring sophisticated health intelligence and research support.

The company's operational footprint and service offerings position it within the healthcare technology and life sciences services sector, which has experienced sustained demand for data-driven insights and analytical capabilities. Quarterly financial disclosures such as the July 28, 2026 announcement provide market participants with regular updates on the company's operational performance and financial condition, enabling informed investment decision-making.

Regulatory Filing Classification and Regulatory Status

The disclosure was filed under Item 2.02 of the current report, relating to results of operations and financial condition. IQVIA is not classified as an emerging growth company, according to the definitions established under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. The company's status as a non-emerging growth company places it under standard reporting and disclosure requirements applicable to established public companies.

The disclosure indicates that the furnished information, while incorporated into the current report filing, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. This designation is standard for press release materials furnished under General Instruction B.2 of the current report form. The information contained within the press release and any incorporated exhibits remains subject to the company's representations and shall not be construed as incorporated by reference into any registration statement or other securities filing except as expressly set forth by specific reference.

Corporate Governance and Executive Signature

The current report was signed on behalf of IQVIA Holdings Inc. by Michael J. Fedock, who holds the position of Executive Vice President and Chief Financial Officer. Fedock's signature on the document certifies that the registrant has duly caused the report to be filed in accordance with Securities Exchange Act requirements. The signature authority granted to the chief financial officer reflects standard corporate governance procedures for public company regulatory filings.

The July 28, 2026 filing date corresponds to the date on which IQVIA issued its press release announcing the second quarter 2026 results. This coordination between the press release issuance and regulatory filing submission reflects standard timing practices for public company earnings announcements, ensuring that disclosure to the market and regulatory authorities occurs substantially contemporaneously.

Business Operations and Corporate Infrastructure

IQVIA Holdings Inc. is incorporated under Delaware law and maintains its principal executive offices at 2400 Ellis Road in Durham, North Carolina. The company's incorporated status in Delaware, a common jurisdiction for large publicly traded corporations, establishes its legal domicile and governance framework. The company's corporate headquarters address serves as the formal contact point for regulatory submissions and shareholder communications.

The company's operational infrastructure supports its service delivery across the global life sciences industry. With commission file number 001-35907 and IRS employer identification number 27-1341991, IQVIA maintains the regulatory identifiers required for SEC reporting and federal tax purposes. These identifiers facilitate the company's compliance with securities regulations and ensure accurate tracking of filings and disclosures within the SEC's electronic data systems.

Financial Results Communication Strategy

IQVIA's approach to communicating quarterly financial results utilizes a coordinated strategy of press release distribution and regulatory filing submission. By posting the full text of the earnings announcement on the company's website and furnishing it simultaneously to the SEC, IQVIA ensures broad dissemination of material financial information to shareholders and market participants. This methodology aligns with standard practices adopted by large-capitalization public companies across the healthcare and technology sectors.

The press release furnished as Exhibit 99.1 serves as the primary vehicle for communicating the detailed financial results and management commentary regarding second quarter 2026 performance. Investors seeking complete details regarding revenue performance, earnings per share, operating margins, guidance updates, or management discussion of business trends should refer to the full text of the press release posted on IQVIA's investor relations website and incorporated into the regulatory filing.

Investor Access to Quarterly Disclosure Materials

The company's disclosure of second quarter 2026 results provides investors with updated information regarding operational performance and financial condition for the period ended June 30, 2026. The press release and accompanying exhibits filed on July 28, 2026, are available through multiple channels including IQVIA's corporate website, the SEC's EDGAR database, and financial information platforms that aggregate publicly filed corporate disclosures.

Investors and analysts monitoring IQVIA's performance may access the complete quarterly results disclosure, including detailed financial statements, management commentary, and forward-looking information, through these distribution channels. The regulatory filing reference number and exhibit designation facilitate location and retrieval of the specific press release and supporting documentation within the SEC's filing system.

Market Context for Healthcare Technology and Life Sciences Services

IQVIA's quarterly earnings announcement occurs within the context of the broader healthcare technology and life sciences services sector. The company's business model centers on providing data analytics and research services to pharmaceutical and healthcare organizations navigating complex regulatory environments and competitive market pressures. Quarterly performance disclosures enable market participants to assess the company's competitive position, revenue trends, and strategic execution within this sector.

The announcement of second quarter 2026 results reflects the company's continued operations in a sector characterized by sustained demand for advanced analytics, regulatory support, and data-driven decision-making capabilities. Healthcare companies and life sciences organizations continue to rely on external partners like IQVIA to support clinical research, regulatory submissions, and market access initiatives, creating ongoing demand for the services and solutions the company provides.

Regulatory Compliance and Financial Reporting Framework

IQVIA's disclosure practices comply with the Securities Exchange Act of 1934 and related SEC regulations governing periodic reporting by publicly traded companies. The filing of the current report on Form 8-K, disclosing the July 28, 2026 announcement of second quarter results, satisfies the company's obligation to disclose material information regarding results of operations and financial condition within prescribed timeframes. The regulatory framework ensures that publicly available information reaches the market in an organized, timely manner.

The distinction between furnished and filed information, as specified in the current report, reflects specific SEC regulations governing the treatment of press releases and exhibits in periodic filings. While the press release is furnished as part of the current report, its designation as furnished information rather than filed information clarifies its regulatory status and any associated liabilities. Investors should understand this distinction when evaluating the legal standing and regulatory implications of statements contained within the announcement.